900000000000526001: REPLACED BY association reference set (foundation metadata concept)

SNOMED CT Concept\SNOMED CT Model Component\Foundation metadata concept (foundation metadata concept)\Reference set\Association type\Historical association reference set (foundation metadata concept)\REPLACED BY association reference set (foundation metadata concept)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2002. Module: SNOMED CT model component module (core metadata concept)

Descriptions:

Id Description Lang Type Status Case? Module

900000000001156010 REPLACED BY association reference set (foundation metadata concept) en Fully specified name Active Entire term case sensitive (core metadata concept) SNOMED CT model component module (core metadata concept)

900000000001157018 REPLACED BY association reference set en Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT model component module (core metadata concept)

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
REPLACED BY association reference set (foundation metadata concept)	Is a	Historical association reference set (foundation metadata concept)	true	Inferred relationship	Some

Members	targetComponentId
Adverse reaction caused by liver preparations and other antianemic agents	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction caused by substance	Adverse reaction (disorder)
Adverse reaction to CNS depressants and anesthetics	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to agent affecting blood constituents NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to agent affecting blood constituents NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to agents primarily affecting blood constituents	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to agents primarily affecting blood constituents	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to anti-infective NOS	Anti-infectives adverse reaction
Adverse reaction to anti-infective NOS	Anti-infectives adverse reaction
Adverse reaction to antiasthmatic NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to anticonvulsant and antiparkinsonism drugs NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to anticonvulsants and anti-parkinsonism drugs	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to antiparkinsonism drug	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to antiparkinsonism drugs NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to biguanide oral hypoglycemic agent	Adverse reaction to biguanide hypoglycemic agent (disorder)
Adverse reaction to bromine compound	Adverse reaction caused by bromine and/or bromine compound (disorder)
Adverse reaction to cardiac glycoside	Adverse reaction to Digitalis glycoside
Adverse reaction to cardiac glycosides NOS	Adverse reaction to Digitalis glycoside
Adverse reaction to central nervous system depressant	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to central nervous system muscle-tone depressants NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to clomocycline sodium	Adverse reaction to clomocycline
Adverse reaction to clorazepate dipotassium	Adverse reaction to clorazepate
Adverse reaction to component of paratyphoid vaccine	Adverse reaction to typhoid vaccine
Adverse reaction to component of vaccine product containing Severe acute respiratory syndrome coronavirus 2 antigen or Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid	Adverse reaction to COVID-19 vaccine
Adverse reaction to dental drugs topically applied	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to drug NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to drug NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to drug primarily affecting the autonomic nervous system NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to drug primarily affecting the cardiovascular system NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to drug primarily affecting the cardiovascular system NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to drugs primarily affecting autonomic nervous system	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to drugs primarily affecting gastrointestinal system	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to drugs primarily affecting gastrointestinal system	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to drugs primarily affecting skin and mucous membrane, ophthalmological, otorhinolaryngological and dental drugs	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to drugs primarily affecting the cardiovascular system	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to drugs primarily affecting the cardiovascular system	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to drugs primarily affecting the gastrointestinal system NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to liver preparations and other antianemic agents NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to other agent affecting blood constituents	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to other agent affecting blood constituents NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to other bacterial vaccine NOS	Adverse reaction to bacterial vaccine
Adverse reaction to other central nervous system depressants and anesthetics	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to other drugs and medicines	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to other drugs and medicines	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to other drugs primarily affecting the gastrointestinal system	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to other muscle drugs	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to other opiates and related narcotics	Opioid analgesic adverse reaction
Adverse reaction to other opiates and related narcotics	Opioid analgesic adverse reaction
Adverse reaction to other psychotropic agent	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to other respiratory system drugs	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to other skin, mucous membrane, ophthalmological, otorhinolaryngological and dental drugs	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to psychotropic agent	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to psychotropic agent NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to skin, mucous membrane, ophthalmological, otorhinolaryngological and dental drugs NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Adverse reaction to sodium cromoglycate	Adverse reaction to cromoglicic acid
Adverse reaction to sodium fusidate	Fusidic acid adverse reaction
Advertising/public relations NOS	Advertising/public relations
Advertising/public relations NOS	Advertising/public relations
Aeroallergen-induced anaphylaxis	Anaphylaxis
Aerobacter aerogenes gastrointestinal tract infection	Gastrointestinal infection caused by Klebsiella aerogenes
Aerobacter meningitis	Meningitis caused by Klebsiella aerogenes
Aeromonas aquariorum	Aeromonas dhakensis
Aeromonas enteropelogenes	Aeromonas trota
Aeromonas tructi	Aeromonas trota
Aeronautical engineer NOS	Aeronautical engineer
Aeronautical engineer NOS	Aeronautical engineer
Aerosol or vapor inhalation for bronchodilation	Inhaled bronchodilator therapy
Aerotherapy NOS	Aerotherapy
Aerotherapy NOS	Aerotherapy
Affect finding	Mood finding
Affective seizure	An epileptic seizure originating within networks limited to one hemisphere presenting with an emotion or the appearance of having an emotion as an early prominent feature, regardless of whether aware or with impaired awareness. Some of these phenomena are subjective and must be recalled and reported by the individual. Emotions involve fear, anxiety, agitation, anger, paranoia, pleasure, joy, ecstasy and other emotions. The seizure also encompasses affective manifestations with the appearance of emotions occurring without subjective emotionality, such as gelastic (laughing) or dacrystic (crying).
Afipia felis	Afipia felis
African trypanosomiasis antibody	Trypanosoma brucei antibody
Agammaglobulinemia	Congenital agammaglobulinemia
Aged parents	Has elderly mother and father (finding)
Aggression caused by ingestible alcohol	Aggression caused by ethanol (finding)
Aggressive digital papillary adenoma	Digital papillary adenocarcinoma
Agriculture machine op. NOS	Agriculture machine operator
Agriculture machine operator NOS	Agriculture machine operator
Agrobacterium radiobacter	Rhizobium radiobacter (organism)
Agrobacterium tumefaciens	Rhizobium radiobacter (organism)
Ahmed tube shunt	Valved ophthalmic drainage device (physical object)
Aids for severely handicapped	Provision of aid for severe disability
Aids for severely handicapped	Provision of aid for severe disability
Air	Air
Air contrast orbitography	Plain X-ray of orbit with contrast (procedure)
Air embolism as a complication of medical care	Air embolism
Air myelogram	Myelogram
Air myelogram	Myelogram
Air pressure effects NOS	Effects of air pressure
Air pressure effects NOS	Effects of air pressure
Air traffic planning/control NOS	Air traffic planning/control
Air traffic planning/control NOS	Air traffic planning/control
Albright hereditary osteodystrophy	A heterogeneous group of endocrine disorders with characteristics of normal renal function and resistance to the action of parathyroid hormone (PTH), manifesting with hypocalcaemia, hyperphosphataemia and elevated PTH levels and that includes the subtypes PHP type 1a (PHP-1a) , PHP type 1b (PHP-1b), PHP type 1c (PHP-1c), PHP type 2 (PHP-2) and pseudopseudohypoparathyroidism (PPHP). PHP-1a, PPHP, and PHP-1b are all due to molecular defects in the same locus of the GNAS (20q13.2-q13.3) gene coding the alpha sub-unit of the stimulatory G protein. PHP can be sporadic or inherited autosomal dominantly with parental imprinting.
Albumin human + epoetin alfa 2.5mg/20000unt injection	Epoetin alfa 20000 unit/mL solution for injection
Albumin human 2.5mg/epoetin alfa 20000iu injection solution vial	Epoetin alfa 20000 unit/mL solution for injection
Albuterol 0.0417% inhalation solution	Salbutamol sulfate 417 microgram/mL solution for inhalation
Albuterol 200micrograms capsule	Salbutamol (as salbutamol sulfate) 200 microgram/actuation powder for inhalation
Albuterol 90mcg/inh aerosol	Product containing only salbutamol in pulmonary dose form (medicinal product form)
Albuterol sulfate + ipratropium bromide	Product containing ipratropium and salbutamol (medicinal product)
Albuterol sulfate + ipratropium bromide 103mcg/18mcg	Ipratropium and salbutamol only product in pulmonary dose form

Start Previous Page 7 of 235 Next End

Reference Sets

Reference set descriptor

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
900000000001156010	REPLACED BY association reference set (foundation metadata concept)	en	Fully specified name	Active	Entire term case sensitive (core metadata concept)	SNOMED CT model component module (core metadata concept)
900000000001157018	REPLACED BY association reference set	en	Synonym (core metadata concept)	Active	Entire term case sensitive (core metadata concept)	SNOMED CT model component module (core metadata concept)